Article
Immunology
Nina Worel, Katharina Grabmeier-Pfistershammer, Bernhard Kratzer, Martina Schlager, Andreas Tanzmann, Arno Rottal, Ulrike Koermoeczi, Edit Porpaczy, Philipp B. Staber, Cathrin Skrabs, Harald Herkner, Venugopal Gudipati, Johannes B. Huppa, Benjamin Salzer, Manfred Lehner, Nora Saxenhuber, Eleonora Friedberg, Philipp Wohlfarth, Georg Hopfinger, Werner Rabitsch, Ingrid Simonitsch-Klupp, Ulrich Jaeger, Winfried F. Pickl
Summary: Studies have found that low levels of CD3(+)CD27(-)CD28(-) T cells in lymphoma patients are associated with a favorable response to CART cell therapy, both in terms of overall response and complete remission. This finding highlights the importance of this pre-infusion blood biomarker in predicting the outcome of CAR-T cell treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Flor Navarro, Noelia Casares, Celia Martin-Otal, Aritz Lasarte-Cia, Marta Gorraiz, Patricia Sarrion, Diana Llopiz, David Reparaz, Nerea Varo, Juan Roberto Rodriguez-Madoz, Felipe Prosper, Sandra Hervas-Stubbs, Teresa Lozano, Juan Jose Lasarte
Summary: The acidification of the tumor microenvironment inhibits the activity of antitumor T cells. Inhibiting the acid loader Ae2 enhances T cell function, while silencing Ae2 or overexpressing Hvcn1 improves the antitumor activity of T cells.
Article
Immunology
Ashi Mannan, Chirag Kakkar, Sonia Dhiman, Thakur Gurjeet Singh
Summary: The concept of using the patient's immune system to fight cancer has been around for some time, but recent progress has been significant. Immune checkpoint blockade and adaptive cell therapy (ACT) are two important approaches that have been approved for treating various types of tumors and have shown promising results.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Wu Ge, Yuqian Dong, Yao Deng, Lujuan Chen, Juan Chen, Muqi Liu, Jianmin Wu, Wei Wang, Xiaoqian Ma
Summary: This review summarizes the similarities and differences of a number of biomarkers for TSTs in several tumor types studied in the last 5 years, as well as the advantages of combining biomarkers. It discusses the possible shortcomings of current biomarkers and highlights strategies to identify TSTs accurately using intercellular interactions, aiming for broader clinical applications of personalized TIL-based ACT.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Teng Wei, Matthias Leisegang, Ming Xia, Kazuma Kiyotani, Ning Li, Chenquan Zeng, Chunyan Deng, Jinxing Jiang, Makiko Harada, Nishant Agrawal, Liangping Li, Hui Qi, Yusuke Nakamura, Lili Ren
Summary: This study explores the use of TCR-engineered T cells in adoptive cell therapy for treating relapsed and metastatic cancers, by utilizing blood-derived T cells and HLA-matched APCs to overcome challenges in isolating PBMCs from advanced-stage cancer patients. The established protocol provides flexibility in identifying neoantigen-specific TCRs when patient PBMCs and tumor material are not available.
Article
Oncology
Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Chiara Musiu, Simone Caligola, Rosalinda Trovato, Alessandra Fiore, Cristina Frusteri, Cristina Anselmi, Ornella Poffe, Tiziana Cestari, Stefania Cane, Silvia Sartoris, Rosalba Giugno, Giulia Del Rosario, Barbara Zappacosta, Francesco Del Pizzo, Matteo Fassan, Erica Dugnani, Lorenzo Piemonti, Emanuela Bottani, Ilaria Decimo, Salvatore Paiella, Roberto Salvia, Rita Teresa Lawlor, Vincenzo Corbo, Youngkyu Park, David A. Tuveson, Claudio Bassi, Aldo Scarpa, Manuela Iezzi, Stefano Ugel, Vincenzo Bronte
Summary: PDAC tumors exhibit strong immunosuppressive characteristics that limit the success of immunotherapy. Research shows that reprogramming the tumor microenvironment by intervening in RNS production can enhance the efficacy of immune-based treatments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Marion Mallet, Rasha E. Boulos, Vincent Alcazer, Paola Bonaventura, Yann Estornes, Nicolas Chuvin, Stephane Depil
Summary: This study compares the efficacy of cancer vaccines and Tg-T cell strategies in different tumor burdens. The study found that high doses of T cell infusion can achieve clinical efficacy, while therapeutic vaccines are more suitable for low or moderate tumor burdens.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Immunology
Guillermo O. Rangel Rivera, Hannah M. Knochelmann, Connor J. Dwyer, Aubrey S. Smith, Megan M. Wyatt, Amalia M. Rivera-Reyes, Jessica E. Thaxton, Chrystal M. Paulos
Summary: The review discusses how targeting metabolic pathways can enhance the immune response of T cells to tumors, as tumors consume key metabolites in the host, depriving T cells of essential nutrients for growth and function. Furthermore, immunosuppressive molecules and checkpoint receptors further compromise the activity of T cells within tumors.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemical Research Methods
Thidarat Kongkaew, Rattapoom Thaiwong, Suparat Tudsamran, Thitiya Sae-jung, Panjana Sengprasert, Apichai Vasuratna, Koramit Suppipat, Rangsima Reantragoon
Summary: This study compared the quality of T cell clones in ovarian cancer TILs using two different expansion methods. The results show that different stimulation methods lead to differences in TIL expansion and TCR repertoire patterns. The standard stimulation method resulted in similar TRBV chains in TIL-expanded clones, but there were also dominant T cell clones in only one subpopulation.
JOURNAL OF IMMUNOLOGICAL METHODS
(2022)
Review
Medicine, Research & Experimental
Jingtao Zhang, Shuai Liu, Xiubao Chen, Xiangdong Xu, Fei Xu
Summary: Lung cancer is a major cause of cancer-related deaths worldwide. Immunotherapies have revolutionized cancer treatment strategies and have the potential to improve immune responses, response rates, and survival rates. However, a deeper understanding of the complex immunological networks in lung cancer is necessary to enhance the efficacy of immunotherapy.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Biology
Dongdong Ti, Miaomiao Bai, Xiaolei Li, Jianshu Wei, Deyun Chen, Zhiqiang Wu, Yao Wang, Weidong Han
Summary: Impaired tumor-specific effector T cells lead to tumor progression and unfavorable clinical outcomes, but adoptive T cell therapy (ACT) has emerged as a promising strategy in cancer treatment, involving ex vivo stimulation and expansion of tumor-infiltrating lymphocytes or genetically modified T cells to provide efficient and long-lasting immune defense against transformed cells.
SCIENCE CHINA-LIFE SCIENCES
(2021)
Review
Immunology
Priyanka Maridhi Nanjireddy, Scott H. Olejniczak, Nataliya Prokopenko Buxbaum
Summary: Genetically engineered CAR T cells have the potential to cure refractory cancers. However, their effectiveness against solid tumors is limited by the immunosuppressive tumor microenvironment. This manuscript provides an overview of CAR T cell metabolism and discusses potential strategies to manipulate metabolic features for improved tumor responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Debottam Sinha, Sriganesh Srihari, Kirrliee Beckett, Laetitia Le Texier, Matthew Solomon, Archana Panikkar, George R. Ambalathingal, Lea Lekieffre, Pauline Crooks, Sweera Rehan, Michelle A. Neller, Corey Smith, Rajiv Khanna
Summary: Studies have shown that overcoming resistance to in vivo T-cell therapy can be achieved through the sequential infusion of two different allogeneic T-cell therapies restricted by different HLA alleles targeting EBV. Furthermore, the combination of inhibition of the programmed cell death protein-1/programmed death-ligand 1 axis with EBV-specific T-cell therapy significantly improves overall survival in tumor-bearing mice.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Dandan Yang, Zhihui Duan, Ping Yuan, Chengming Ding, Xiaoming Dai, Guodong Chen, Daichao Wu
Summary: TCR-engineered T cells have made significant progress in solid tumor therapy, with potential for further improvement in antigen selection and therapy strategies.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Engineering, Biomedical
Hye Sung Kim, Tzu-Chieh Ho, Moshe J. Willner, Michael W. Becker, Hae-Won Kim, Kam W. Leong
Summary: In this study, we propose an ex vivo T cell expansion system that mimics natural antigen-presenting cells for adoptive cell therapy. The system utilizes microfiber scaffolds coated with dendritic cell membrane to replicate the physicochemical properties of dendritic cells, leading to greater expansion and functionality of T cells. This scalable and customizable platform holds promise for future research and application in cell therapy.
BIOACTIVE MATERIALS
(2023)